ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Secondary Prevention of Osteoporosis

This study has been completed.

Sponsors and Collaborators: National Institute on Aging (NIA)
Merck
GlaxoSmithKline
Information provided by: National Institute on Aging (NIA)
ClinicalTrials.gov Identifier: NCT00421343
  Purpose

The purpose of this study is to develop and implement an evidence based protocol for the secondary prevention of osteoporotic fractures and falls, and to determine how compliance with this intervention improves muscle strength and functional status following a fracture.


Condition Intervention Phase
Osteoporosis
Drug: alendronate with cholecalciferol
Drug: calcium carbonate with cholecalciferol
Behavioral: Falls prevention measures
Phase III

MedlinePlus related topics:   Fractures    Osteoporosis    Rehabilitation   

Drug Information available for:   Alendronate    Alendronate sodium    Calcium gluconate    Calcium carbonate    Cholecalciferol   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:   Secondary Prevention of Osteoporosis: A Window of Opportunity in the Acute Rehabilitation Setting

Further study details as provided by National Institute on Aging (NIA):

Primary Outcome Measures:
  • Changes in functional status and muscle strength [ Time Frame: 6-months post fracture ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in vitamin D levels [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • satisfaction with the intervention [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • reasons for adherence/non-adherence with the intervention [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment:   27
Study Start Date:   February 2007
Study Completion Date:   June 2008
Primary Completion Date:   June 2008 (Final data collection date for primary outcome measure)

Intervention Details:
    Drug: alendronate with cholecalciferol
    alendronate 70mg /cholecalciferol 2800IU orally once weekly
    Drug: calcium carbonate with cholecalciferol
    calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
    Behavioral: Falls prevention measures
    personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
Detailed Description:

Following a fracture, few persons are screened or treated for osteoporosis (Feldstein et al). It is not surprising, then, that the risk of future osteoporotic fractures remains high. Although little data exists on the secondary prevention of osteoporosis, calcium, vitamin D, and bisphosphonates have all been shown to be effective in the primary prevention of osteoporotic fractures, and they are likely beneficial in reducing secondary fractures as well. Targeting falls prevention is another approach that is likely effective in reducing the risk of fracture.

In the U.S., acute rehabilitation (rehab) settings offer a unique environment to initiate osteoporotic therapy. Therefore, this study will develop and implement evidence based interventions for the secondary prevention of osteoporotic fractures in the acute rehab setting with the following objectives:

Specific Aim I: Assess overall compliance with pharmacological and non-pharmacological interventions initiated in an acute rehab setting following a fragility fracture. Hypothesis: Non-compliant participants are less likely to show improvement in functional status, muscle strength, or vitamin D levels following the intervention.

Specific Aim II: Describe the incidence of fragility fractures and falls in participants at 6-months and one-year following the osteoporotic intervention introduced during acute rehab. Hypothesis: Similar to community based studies, a number of participants will go on to experience repeat falls and resulting fractures within one-year of follow-up. Compliant participants are less likely to experience falls and fractures.

Specific Aim III: Confirm the high prevalence of vitamin D deficiency in a rehab setting. Describe the relationship between changes in vitamin D levels in participants between baseline and 6-month follow-up and changes in functional outcomes. Hypothesis: There will be a direct association between a change in vitamin D levels and a change in functional status.

Consecutive individuals admitted with the primary or secondary diagnosis of fracture in the rehabilitation unit of Hebrew Rehabilitation Center will be offered enrollment. All participants enrolled will receive the same intervention: calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention interventions. Specific interventions for preventing falls include optimization of visual acuity, a review of medications associated with falls, personalized exercises to improve strength and balance, and a home hazards safety evaluation when indicated.

All participants will have their functional status, muscle strength, and vitamin D level measured at baseline during their rehab stay. At the six-month follow-up, a home visit will be performed for all participants to again assess functional status, muscle strength, vitamin D level, satisfaction with the intervention, and reasons for non-compliance. A history of interim falls and fractures will be collected by telephone interviews, during home nursing visits, and during the exit 6-month visit.

  Eligibility
Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Admitted to rehab unit with the primary or secondary diagnosis of fracture
  • English speaking
  • Cognitively able to provide consent or health care proxy available and willing to provide consent
  • Willing to cooperate

Exclusion Criteria:

  • Pathologic or periprosthetic fractures
  • Creatinine clearance less than 15ml/minute
  • Severe hypocalcemia
  • Esophageal stricture or achalasia
  • Taking other treatment for osteoporosis besides calcium or vitamin D in the past 6-months
  • History of kidney stones in the past 6-months
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00421343

Locations
United States, Massachusetts
Hebrew SeniorLife    
      Boston, Massachusetts, United States, 02131

Sponsors and Collaborators
National Institute on Aging (NIA)
Merck
GlaxoSmithKline

Investigators
Principal Investigator:     Sarah D Berry, MD, MPH     Harvard University, Hebrew Rehabilitation Center    
  More Information


Publications:

Responsible Party:   Harvard University, Hebrew Rehabilitation Center ( Sarah D. Berry, MD, MPH )
Study ID Numbers:   AG0074, 5 T32 AG023480-03
First Received:   January 10, 2007
Last Updated:   August 28, 2008
ClinicalTrials.gov Identifier:   NCT00421343
Health Authority:   United States: Federal Government

Keywords provided by National Institute on Aging (NIA):
disease/disorder proneness/risk  
osteoporotic fractures  
accidental falls  
aging  

Study placed in the following topic categories:
Cholecalciferol
Musculoskeletal Diseases
Alendronate
Fractures, Bone
Neoplasm Metastasis
Osteoporosis
Bone Diseases, Metabolic
Calcium Carbonate
Bone Diseases

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Growth Substances
Vitamins
Physiological Effects of Drugs
Bone Density Conservation Agents
Antacids
Micronutrients
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers